Clinical research is the basic feature that allows medicines to be authorized with the guarantees required by law and ultimately to become part of clinical practice for the benefit of patients. It also allows new forms of use to be researched once the medicines are already commercialized.
In short, clinical research enables the generation of high quality knowledge to develop therapeutic tools that improve those already available, and which contribute to the prevention, relief and cure of diseases and to the improvement of people´s quality of life.
RESEARCHER:
Dr. Jesús Merayo LlovesRECLUTANDO
Double masked SYL1001 study in patients with moderate or severe dry eye disease
INDICATION: Patients with moderate to severe dry eye
TREATMENT: SYL1001
PROMOTOR: SYLENTIS
RESEARCHER:
Dr. Álvaro Fernández-Vega Sanz RECLUTANDO
INDICATION: Macular edema secondary to occlusion of the central
TREATMENT: Aflibercept
PROMOTOR: Bayer AG
RESEARCHER:
Dr. Álvaro Fernández-Vega Sanz ACTIVOPhase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC)
INDICATION: Patients with polypoid choroidal vasculopathy
TREATMENT: Aflibercept
PROMOTOR: AIBILI
RESEARCHER:
Prof. Luis Fernández-Vega Sanz RECLUTANDOA dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)
INDICATION: Pacientes con degeneración macular asociada a la edad (DMAE húmeda).
TREATMENT: OPT-302
PROMOTOR: OPTHEA
RESEARCHER:
Dr. Álvaro Fernández-Vega Sanz ACTIVOTreatment of age-related macular degeneration of the neovascular type (DMAEh) over 2 years with a treatment and extension model (T + E) of 2 mg aflibercept injected into the eye.
INDICATION: Patients with Macular Degeneration Associated with the Wet Age
TREATMENT: Aflibercept
PROMOTOR: Bayer AG
RESEARCHER:
Dr. Jesús Merayo Lloves RECLUTANDO"Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye"
INDICATION: Pacientes con ojo seco leve o moderado
TREATMENT: AVX-012
PROMOTOR: Avizorex Pharma
RESEARCHER:
Dr. Jesús Merayo Lloves ACTIVOA multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.
INDICATION: Moderate to severe dry eye
TREATMENT: Ciclosporina
PROMOTOR: Mc2 biotec- Iris Pharma
RESEARCHER:
Dr. Jesús Merayo Lloves FINALIZADOEfficacy and safety of T4020 versus its vehicle in patients with chronic neurotrophic keratitis or corneal ulcer.
